FindMyRecallSubscribe
Class III: unlikely to cause harmOngoing

Cipla Nilotinib Capsules Recall

Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for:…

Cipla USA, Inc. · Warren, NJ

Risk level
Class III
Reported by FDA
Mar 11, 2026
Recall ID
D-0382-2026
Check your lot numberHow we source this data

Summary

Cipla recalled Nilotinib Capsules starting Feb 18, 2026. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-0382-2026 on Mar 11, 2026. Reason: Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test. Status: Ongoing.

Why it was recalled

Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.

Product description

Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each), NDC 69097-032-74; Inner carton: 28 capsules (4 blisters of 7 capsules), NDC 69097-032-56; Foil blister: NDC 69097-032-17

Lot numbers, UPCs & expiration codes

Lot #: 5GJ0223, Exp 04/30/2027

Where it was sold

U.S.A. Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0382-2026
Classification
Class III
Status
Ongoing
Recall initiated
Feb 18, 2026
FDA report date
Mar 11, 2026
Quantity
164 cartons
Recall type
Voluntary: Firm initiated
Recalling firm
Cipla USA, Inc.

Original FDA data

Every field from FDA enforcement report D-0382-2026, exactly as published.

Show all FDA fields
City
Warren
State
NJ
Status
Ongoing
Country
United States
Event ID
98452
Address
10 Independence Blvd
Code information
Lot #: 5GJ0223, Exp 04/30/2027
Postal code
07059-2730
Report date
Mar 11, 2026
Product type
Drugs
Recall number
D-0382-2026
Classification
Class III
Recalling firm
Cipla USA, Inc.
Product quantity
164 cartons
Reason for recall
Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each), NDC 69097-032-74; Inner carton: 28 capsules (4 blisters of 7 capsules), NDC 69097-032-56; Foil blister: NDC 69097-032-17
Distribution pattern
U.S.A. Nationwide
Recall initiation date
Feb 18, 2026
Initial firm notification
Letter
Center classification date
Mar 3, 2026

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0382-2026, published Mar 11, 2026. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls